Abstract
Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.
Original language | English (US) |
---|---|
Pages (from-to) | 22-42 |
Number of pages | 21 |
Journal | International Reviews of Immunology |
Volume | 31 |
Issue number | 1 |
DOIs | |
State | Published - Feb 2012 |
Keywords
- CRT
- Cancer vaccines
- EGFR
- HNSCC
- HPV
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology